pharmaceutical

Amneal Pharmaceuticals surged 3.76% after agreeing to acquire Kashiv BioSciences for $1.1 billion, positioning itself in the $300 billion biosimilars market.

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

J&J transforms from income stock into growth engine with 50% rally in 12 months, backed by innovative medicines and medical device expansion despite 2026 patent cliff.

Upsher-Smith launches digital support platforms for DMD treatment KYMBEE, enhancing patient access and clinician resources through comprehensive support program.

Sun Pharma finalizes $12B binding offer for Organon, marking India's largest overseas pharma acquisition amid industry consolidation.

Johnson & Johnson's 63-year dividend streak and AAA rating offer security, but 2.2% yield falls short of 4% income targets, requiring complementary holdings.

Global centrifugal separator market projected to reach $10.14B by 2035 from $4.62B in 2025, growing at 7.3% CAGR driven by pharma, biotech, and food processing demand.

Sysco, McCormick, and Eli Lilly announce $78B in major acquisitions spanning foodservice, consumer staples, and pharma, signaling significant industry consolidation.

AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.

Three sectors announce buybacks: Constellation Energy's $5B signals confidence despite 20% decline; Novo Nordisk's modest 15B DKK raises concern; Carnival's $2.5B backed by strong results.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.

Johnson & Johnson shares dropped under 2% as S&P 500 fell 7%, backed by $94.2B revenue, 6% growth, and 63 consecutive dividend increases, though talc lawsuits and Medicare price negotiations pose headwinds.

Three dividend stocks—Philip Morris, Pfizer, and UnitedHealth—offer compelling long-term value despite significant recent declines, supported by healthcare demographics and business transformation.

XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.

Agios Pharmaceuticals surges on FDA accelerated approval for mitapivat sickle cell treatment, enabling faster path to full approval despite company's ongoing losses.

Waste Management and Gilead Sciences offer attractive dividend-growth opportunities as pullbacks from Middle East tensions create entry points for AI-driven productivity investors.

Teva gains FDA approval for PONLIMSI denosumab biosimilar and dual regulatory acceptance for omalizumab candidate, advancing biosimilar growth strategy.

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.

Ionis Pharmaceuticals cuts Tryngolza price from $595K to $40K annually, positioning for broader FDA approval and potential $2B+ peak sales.

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly failing to disclose FDA deficiencies in Anaphylm NDA, causing 37% stock decline.